Clarus Therapeutics Holdings, Inc.
http://www.clarustherapeutics.com/index.htm
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clarus Therapeutics Holdings, Inc.
Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window
Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.
Tech Transfer Roundup: Novo Nordisk Foundation, Broad Institute Team On Genomic Drivers Of Disease
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals